Search for:
Product Regulation & Liability

United Kingdom & United States: Healthcare & Life Sciences patent enablement and what it means for your transactions or litigation

By , and 1 Min Read

Healthcare & Life Sciences Patent Enablement and What It Means for Your Transactions or Litigation

Date & Time

13 February 2024 | 09:00 – 10:00 US (CST)

REGISTER

ADD TO CALENDAR

The requirement that an inventor provides an enabling disclosure of their invention in exchange for patent protection lies at the heart of the patent system and is a central consideration for organizations across innovative sectors especially those in life sciences and pharmaceuticals. Recent decisions have recast the way that global courts and intellectual property offices are considering enablement issues, with wide-reaching impacts for patent procurement, enforcement and technology transactions.

This webinar delves into the dynamic landscape of patent enablement and plausibility standards, comparing and contrasting the nuanced approaches adopted in the US and Europe. In this session, we will discuss these recent developments, with a special focus on what they mean with respect to licensing, M&A and other transactions in the healthcare space and how you can anticipate issues as they arise in deals.

REGISTER

Categories:
Author

Jessie’s practice includes intellectual property (IP) support in business transactions, coordination of global patent assignments and recordals, global patent portfolio strategy and management, and patent prosecution. Prior to entering law school, she earned her doctorate in Plant Pathology and Microbiology focusing on iron regulatory networks of bacterial pathogens. This technical background has lent nicely to her focus on patent matters, especially those pertaining to life sciences and biotechnology.

Author

Oren Livne is a partner in the Transactions Practice Group and the Life Sciences Industry Group. Before beginning his legal career, Oren co-founded a university technology transfer office and managed its licensing operations, which, together with his M.B.A, from New York University's Leonard N. Stern School of Business, provide a unique business perspective that he leverages for the benefit of the firm's clients.

Author

Hiroshi Sheraton's practice covers all aspects of intellectual property law with a particular emphasis on contentious patent and trade mark matters and life sciences. Much of his work is cross-border in nature. He regularly co-ordinates pan-European and global IP litigation and advises clients on international IP strategies for patent litigation and brand protection. He represents clients in the UKIPO, EPO, OHIM, the English Courts and the CJEU. He has experience of IP matters across Europe and has litigated IP cases in Germany, France, Spain, Italy, the Netherlands, Belgium, Austria, Ireland, Northern Ireland and Luxembourg, the USA and Asia Pacific. Although he has a first degree in biochemistry and molecular biology, he covers all areas of technology from pharmaceuticals/biotech products and agrochemicals to electronics and software.

Related Posts